The fundamental modes of treatment for type 2 diabetes are aerobic exercise and energy restriction, and these regimes increase insulin sensitivity. 7) However, few patients are able to achieve a satisfactory control of blood glucose. The most commonly used oral antidiabetic agents have been sulfonylureas. These agents increase insulin secretion from pancreatic b-cells, but sometimes induce severe hypoglycemia and weight gain, 8) and hyperinsulinemia is known to be a risk factor for ischemic heart disease. 9) In addition, high rates of both primary and secondary failure are observed with these drugs. [10] [11] [12] [13] Therefore, drugs that ameliorate the insulin resistance without stimulating insulin release from b-cells have been developed for the treatment of type 2 diabetes.
The prototypical 2,4-thiazolidinedione, ciglitazone (1) 14) (Chart 1) was discovered by our company, and has antihyperglycemic activity in insulin-resistant animal models, KKA y mice 15) and Wistar fatty rats, 16) but no effect in insulin-deficient animal models of diabetes. 17, 18) During structure-activity relationship studies on 2,4-thiazolidinediones and related compounds, we discovered highly potent compounds, such as pioglitazone (2) , 19) and AD-5061 (3) 20) (Chart 1). Since the discovery of ciglitazone (1), a number of pharmaceutical companies have been evaluating new 2,4-thiazolidinedione analogs as agents for improving insulin resistance. Troglitazone (4) 21) was launched first in the market, but had been withdrawn because of liver toxicity and related deaths associated with the drug. Nowadays, two 2,4-thiazolidinedione class agents, pioglitazone (2) and rosiglitazone (5) 22) are clinically used. (Chart 1). Many companies are still endeavoring to find a new glucose lowering agent. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Although the precise mechanism of action of these drugs remains unknown, recent study suggests that antidiabetic thiazolidinediones interact with a family of nuclear receptors known as peroxisome proliferator-activated receptor (PPAR)-g. 36) PPARg is one of a subfamily of PPARs encoded by independent genes. Three human PPARs, designated PPARa, PPARg, and PPARd, have been identified to date. [37] [38] [39] It was also observed that the potency for activation of PPARg in vitro mirrored the in vivo glucose lowering activity in diabetic ob/ob mice. 40) This would indicate that the major mechanisms of action of 2,4-thiazolidinediones involve PPARg.
In the case of those 2,4-thiazolidinediones already on the market, several side effects, such as anemia, edema, and body weight gain, have been reported. 41) Naturally it occurs to us to find a new class of compounds with fewer side effects and a more advanced profile than known 2,4-thiazolidinediones. Thus, we focused on the search for a new series of non-thiazolidinedione compounds with potent antihyperglycemic activity in insulin-resistant animal models.
First, we selected (Z)-(4-chlorobenzyloxyimino)phenylacetic acid (6) (Fig. 1) as a seed compound. Compound (6) was found from our in vivo KKA y mice screening to search for novel glucose and lipid lowering agents. Although compound (6) has weak antihyperglycemic activity (data not shown), we paid attention to its unique structure. There have been several reports of non-thiazolidine glucose and lipid lowering agents. [28] [29] [30] [31] 33) However, oxyiminoacetic acid derivatives as such agents have not been reported to our knowledge. For that reason, much effort was made to find more potent oxyiminoacetic acids. Compounds synthesized were evaluated first by in vivo KKA y mice screening. Although in vivo evaluation as first screening might not be efficient than in vitro evaluation in general, the screening using KKA y mice, which has been well established to develop pioglitazone (2), 19) takes only 4 d to evaluate compounds. In addition, compounds having poor pharmacokinetic properties would remove at the early stage of development.
Early in the modification, we found that replacement of the chloro moiety in 6 with the (5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy moiety enhanced the potency [compound (7), Fig. 1 ]. Encouraged by this result, we planned to synthesize a new series of oxyiminoacetic acids (structure A, Fig. 1 ) to investigate the effect of the phenyl group of 7, which is positioned a to the carboxyl group, as antidiabetic agents. In this paper, we describe the synthesis, structure-activity relationships (SARs), and biological analysis of oxyiminoacetic acids.
Chemistry
The general preparation procedure of oxyiminoacetic acids and their derivatives is outlined in Chart 2. The starting benzaldehyde (8) was reduced by sodium borohydride to give benzyl alcohol (9) . Treatment of 9 with thionyl chloride gave benzyl chloride (10) . Alkylation of oximes (11) with 10 gave alkoxyiminoacetates (12) . Saponification of 12 with aqueous NaOH afforded acetic acid derivatives (13) .
The methods for preparation of intermediates (11) in Chart 2 are shown in Charts 3-5. Friedel-Crafts acylation of substituted benzenes with ethyl oxalyl chloride gave phenylglyoxylates (14) , which were treated with hydroxylamine to provide oximes (11d, e) as a mixture of E-and Z-isomers (Chart 3). These isomers were easily separated by column chromatography.
Several oximes were prepared by another method (Chart 4). Diethyl oxalate was converted into a-ketoesters by a reaction with Grignard reagents (Rϭbutyl, isopropyl, and 4-bromophenyl), or with ethyl phenylacetate in NaOEt/EtOH solution followed by de-ethoxycarbonylation (Rϭbenzyl). The resultant ketoesters were treated with hydroxylamine to give oximes (11b, h-j), the isomers of which were separated by column chromatography.
Chart 5 shows the method used for preparing ethyl (3-substitutedphenyl)glyoxylate oxime derivatives [11c (RϭBr) and 11f (Rϭphenoxy)]. Mesylation of 3-phenoxybenzyl alcohol (16) was followed by treatment with sodium iodide and a reaction with sodium cyanide to provide 3-phenoxybenzyl cyanide (17b). Benzyl cyanides [17a (RϭBr: commercially available) and 17b (Rϭphenoxy)] were reacted with isoamyl nitrite to give compounds (18a, b), which were treated with KOH and esterified subsequently to give the desired 11c and 11f. The E-and Z-isomers of 11c and 11f were also separated by column chromatography.
In case of aromatic R 1 in Fig. 2 , the configuration of 11 was presumed by normal phase thin layer chromatography (TLC). Less polar isomer of 11 on TLC might have Z configuration, because the existence of hydrogen bonding between hydroxime hydrogen and carbonyl oxygen, which diminishes polarity, could be considered. With regard to methyl 2-(hydroxyimino)-2-phenylacetate (11a), the configurations were determined by 1 H-NMR NOESY experiments (Fig. 3) . A nu-clear Overhauser effect (NOE) was observed between H a and H b of the polar isomer of 11a, which was proved to have E configuration. On the other hand, no NOE was observed between H c and H d of the less polar isomer of 11a, which was turned out to have Z configuration. These results are considered to support the validity of the predictions of the configuration using TLC. In cases of 11h and 11j, which have aliphatic R in Chart 4 (11h, Rϭbutyl; 11j, Rϭbenzyl), single isomers were obtained. The configuration is presumed as E, because 11i (Rϭisopropyl) was obtained as a mixture of isomers probably by reason of steric repulsion between hydroxy group and bulky isopropyl group. Compounds (29, 30) were prepared by Suzuki coupling of the appropriate (phenyl or styryl) boronic acid with 19 and subsequent saponification with aqueous NaOH (Chart 6).
The analytical data of the synthesized oxyiminoacetic acids (7, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) are shown in Table 1 .
Results and Discussion
The biological activities of the compounds prepared (7, 20-35) were tested using genetically obese and diabetic KKA y mice. 15) The results are shown in Table 2 . We initially examined the effect of introducing a functional group to the phenyl ring of 7, which is positioned a to the carboxyl group. Introduction of a bromo group as an electron withdrawer at the meta-or para-position increased the potency in vivo (21, 23 vs. 7). Introduction of a methoxy group as an electron donator at the para-position did not affect the activity (24 vs. 7), whereas introduction of a larger phenoxy group at the same position markedly increased activity. Compound (25) significantly reduced plasma glucose (33%, pϽ0.01) and plasma triglycelide levels (43%, pϽ0.01) even at a dosage of 0.001% in diet. Introduction of a phenyl group or a styryl group instead of a phenoxy group in 25 did not increase potency (29, 30 vs. 25) . Attachment of a phenoxy group at the meta-position decreased potency (27 vs. 25) . Those results indicate that an introduction of bulky, but not solid structure at the para-position of the phenyl group is important to increase in vivo potency.
Between the two regioisomers of oxime, the Z-configuration seemed to be more potent than the E-configuration (21 vs. 22; 25 vs. 26; etc.), while compound (26) , which has the E-configuration, caused a significant reduction in the plasma glucose level (30%, pϽ0.05) at a dosage of 0.01% in diet in KKA y mice. Therefore, it could be said that the recognition of the configuration of the oximes is somewhat loose for in vivo potency.
An exchange of the phenyl ring positioned a to the carboxyl group for alkyl moieties did not increase potency (31, 32, 34, 35) except in 33. Compound (33) significantly reduced of plasma glucose (38%, pϽ0.01) and plasma triglycelide levels (66%, pϽ0.01) at a dosage of 0.01% in diet. Taking into account the fact that only 33 has Z-configration among compounds (31-35), the results described above support our assumption that the Z-configration is more potent than the E-configuration.
To clarify whether the mechanisms of action of the oxyiminoacetic acid derivatives involved PPARg or not, the functional potency at PPARg of several compounds was investigated. Compounds (7, 25, 33) were selected on the basis of their activity in KKA y mice. As shown in 
a) Maximum reductions in plasma glucose and plasma triglyceride levels at a dosage of 0.001, 0.01, or 0.03% in the diet were calculated as percent reduction with respect to the control value. b) L indicates less than a 15% reduction at that dose. (25) showed particularly strong antidiabetic activity. Several selected compounds exhibited PPARg transcriptional activity. This means that the mechanisms of action of the oxyiminoacetic acid derivatives involve PPARg, at least in part. Pharmacokinetic analysis showed that compound (25) possessed very good pharmacokinetic characteristics. Further structural modification of oxyiminoacetic acid and an expanded SAR study will be discussed in our next paper.
Experimental Biological Procedures. (a) Glucose and Lipid Lowering Experiments
The glucose and lipid lowering activities of the compounds were tested using KKA y mice. 15) After being fed a powdered laboratory chow (CE-2, Clea Japan, Inc., Tokyo, Japan) over 3 d, female mice (9-13 weeks old) were divided into experimental groups of five animals each based on their blood glucose levels. The test compounds were given as a dietary admixture at 0.03, 0.01, or 0.001% in the diet. The mice were fed the experimental diet and water ad libitum for 4 d. Blood samples were taken from the orbital vein. The plasma glucose levels were determined enzymatically using Iatrochem-GLU(A) (Iatron Laboratories, Inc., Tokyo, Japan) or L type Wako Glu 2 (Wako Pure Chemical Ind., Ltd., Tokyo, Japan). The plasma triglyceride levels were also determined enzymatically using Iatro-MA701 TG kits (Iatron Laboratories, Inc.) or L type Wako TG · H (Wako Pure Chemical Ind., Ltd.). The respective values are shown as percent reduction with respect to the control value. A 0.001% dosage was approximately 1.3-1.6 mg/kg/d. In case of diabetic KKA y mice, the control values of PG and TG were approximately 450-550 mg/dl and 550-700 mg/dl, respectively. In case of normal C57BL mice, the values of PG and TG were approximately 200 mg/dl and 80 mg/dl, respectively.
(b) PPARg g-Retinoid X Receptor a a (RXRa a) Heterodimer Transactivation Assay The full-length human PPARg1, full-length human RXRa and PPAR responsive luciferase reporter were stably expressed in CHO-K1 cells. These cells were cultured in HAM F12 medium (NISSUI SEIYAKU) containing 10% fetal bovine serum (Life Technologies, Inc., U.S.A.), inoculated into a 96-well white plate (Corning Coaster Corporation, U.S.A.) at a density of 2ϫ10 4 cells/well, and cultured in a carbonate gas incubator at 37°C overnight. The 96-well white plate was washed with PBS (phosphatebuffered saline), and 90 ml of HAM F12 medium containing 0.1% fatty acidfree bovine serum albumin (BSA) and 10 ml of test substance were added. The plate was then cultured in the carbonate gas incubator at 37°C for 48 h. The medium was removed, 40 ml of PICAGENE 7.5 (Wako Pure Chemical Ind., Ltd.) was added, and after stirring, luciferase activity was determined using Lumistar (BMG Labtechnologies GmBH, Germany). Induction magnitude was calculated based on the luciferase activity of each test substance with the luciferase activity in the non-treatment group assigned a value of 1. The values of concentration and induction magnitude were analyzed using a PRISM 2.01 (GraphPad Software Inc., U.S.A.) to calculate the EC 50 , the effective concentration of test compound required to induce 50% of the maximum activity.
Pharmacokinetic Analysis. (a) Single-Dose Pharmacokinetics Experiments were carried out in SD (IGS) rats (8 weeks old, male). The animals were fed the CE-2 diet and water ad libitum. They were dosed with the drug at 1 mg/kg/i.v. as an N,N-dimethylacetamide-PEG 400 (1 : 1) solution, or at 10 mg/kg/p.o. as a 0.5% MC suspension. Blood samples were collected at different time points (pre, 5, 10, 15, 30 min, 1, 2, 4, 8, 24 h for the intravenous study; pre, 15, 30 min, 1, 2, 4, 8, 24 h for the oral study, respectively) from a tail vein. The samples were analyzed by HPLC to calculate pharmacokinetic parameters such as AUC 0-24 h , C 5 min , C max , T max , T 1/2 , and bioavailability. AUC 0-24 h is the area under the drug plasma concentration versus time curve. C 5 min is the observed plasma concentration 5 min after administration. C max is the observed maximum plasma concentration. T max is the time at which C max is achieved. T 1/2 is the half-life of the drug. Bioavailability is calculated by the following formula:
(b) Analysis of Plasma Samples (i) Sample Preparation: Acetonitrile was added to each plasma sample (100 ml). The mixture was stirred by irradiation with supersonic waves before centrifugal separation was carried out. The supernatant liquid was subjected to centrifugal condensation under reduced pressure at 30°C. The residue was dissolved in acetonitrile-0.01 mol/l ammonium acetate (55 : 45, v/v, 200 ml). The mixture was stirred by irradiation with supersonic waves. Then centrifugal separation was carried out to remove insoluble substances. The supernatant liquid was used for HPLC analysis.
(ii) HPLC Assay: Inertsil ODS-3 (f 4.6ϫ250 mm) was used for HPLC analysis. Analyses of compounds were carried out using acetonitrile-0.01 mol/l ammonium acetate (55 : 45, v/v) as a mobile phase at a flow rate of 1.0 ml/min at 40°C, and the detection wavelength was 270 nm. Under these conditions, the retention time for 25 was 21.6 min.
Chemical Methods Melting points were recorded on a Yanagimoto micro melting point apparatus and are uncorrected. Elemental analyses (C, H, N) were carried out at Takeda Analytical Research Laboratories, Ltd., and all values are within Ϯ0.4% of calculated values unless otherwise noted. IR spectra were recorded on a JASCO IR-810. Ϫ78°C for 1 h, the reaction mixture was allowed to warm to 0°C. (e) Ethyl (E)-2-(4-bromophenyl)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}acetate (600 mg, 1.09 mmol) was dissolved in THF (6 ml)-MeOH (3 ml), and 1 M NaOH (3 ml) was added to the mixture. The whole was stirred at 40°C for 1 h, then made acidic by addition of 1 M HCl (3.3 ml) and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was recrystallized from AcOEt-hexane to give 22 (561 mg, 99%) as colorless crystals. mp 159-160°C (dec. (b) A mixture of 2-(3-bromophenyl)-2-(hydroxyimino)acetonitrile (18a, 19.0 g, 84.4 mmol), 4 M KOH (100 ml) and 2-methoxyethanol (100 ml) was refluxed for 4 h. After cooling to room temperature, the mixture was made acidic by addition of 1 M HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in EtOH (200 ml), and conc. H 2 SO 4 (catalytic amount) was added. The whole was refluxed for 48 h, then cooled to room temperature, diluted with aqueous sodium hydrogen carbonate and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane 3 ml, 200 mmol) was added dropwise to a suspension of aluminum chloride (29.3 g, 220 mmol) in CH 2 Cl 2 (250 ml) at 0°C under nitrogen, and the mixture was stirred at 0°C for 0.5 h. The mixture was added dropwise over a period of 0.5 h to diphenyl ether (63.5 ml, 400 mmol) at 0°C. The whole was stirred at 0°C for 2 h, then poured onto ice (250 g). After stirring at room temperature for 1 h, the organic layer was separated, washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 10, v/v) to give ethyl (4-phenoxyphenyl)glyoxylate (38.0 g, 70%) as a colorless oil. (Z)-2-{4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-(3-phenoxyphenyl)acetic Acid (27) (a) Methanesulfonyl chloride (14.6 ml, 188 mmol) was added to a solution of 3-phenoxybenzyl alcohol (16, 25 .0 g, 125 mmol) and triethylamine (26.3 ml, 188 mmol) in AcOEt (300 ml) at 0°C, and the mixture was stirred for 1 h. The mixture was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in acetone (300 ml), then sodium iodide (37.5 g, 250 mmol) was added to the solution. The whole was stirred at room temperature for 1 h. After evaporation of the solvent, the residue was dissolved in water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was dissolved in DMSO (100 ml), then sodium cyanide (7.35 g, 150 mmol) was added to the mixture. The whole was stirred at room temperature for 15 h, then diluted with AcOEt. The mixture was washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 7, v/v) (c) A solution of 2-(hydroxyimino)-2-(3-phenoxyphenyl)acetonitrile (18b, 3.00 g, 12.6 mmol) and KOH (3.40 g, 60.4 mmol) in EtOH (15 ml)-water (15 ml) was refluxed for 24 h. After cooling to room temperature, the mixture was made acidic by addition of 1 M HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in MeOH (30 ml), then conc. H 2 SO 4 (catalytic amount) was added. The whole was refluxed for 24 h. After cooling to room temperature, the mixture was diluted with aqueous sodium hydrogen carbonate and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 2, v/v) to give less polar ethyl (Z)-2-(hydroxyimino)-2-(3-phenoxyphenyl)acetate [(Z)-11f, 1.14 g, 33%] as a yellow oil and polar ethyl (E)-2-(hydroxyimino)-2-(3-phenoxyphenyl)acetate [(E)-11f, 746 mg, 22%] as crystals. Recrystallization of (E)-11f from AcOEt-hexane gave colorless crystals. The data for (Z) , toluene (20 ml), EtOH (2 ml), and water (2 ml) was stirred at room temperature under argon for 0.5 h. To this was added tetrakis(triphenylphosphine)palladium(0) (105 mg, 0.091 mmol), and the mixture was refluxed for 14 h. After cooling to room temperature, the mixture was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 3, v/v) to leave an oil. The oil was dissolved in THF (10 ml)-MeOH (5 ml), and 1 M NaOH (5 ml) was added to the mixture. The whole was stirred at 40°C for 2 h, then made acidic by addition of dil. HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was recrystallized from AcOEt-hexane to give 30 (634 mg, 77%) as pale-yellow crystals. mp 194-195°C (dec.). 2-{4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-hexanoic Acid (32) (a) Butylmagnesium chloride (0.90 M solution in THF, 100 ml, 90 mmol) was added dropwise to a solution of diethyl oxalate (26.3 g, 180 mmol) in Et 2 O (400 ml) at Ϫ78°C under nitrogen. The mixture was stirred at Ϫ78°C for 1 h, then allowed to warm to 0°C, and added dil. HCl. The organic layer was separated, washed with aqueous sodium hydrogen carbonate and brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in EtOH (150 ml), then hydroxylamine hydrochloride (7.50 g, 108 mmol) and sodium acetate (11.1 g, 135 mmol) were added to the mixture. The whole was refluxed for 13 h. After evaporation of the solvent, the residue was dissolved in water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 4, v/v) to give ethyl (E)-2-(hydroxyimino)hexanoate [(E)-11h, 11.0 g, 71%] as crystals. Recrystallization from hexane gave colorless crystals (8.26 g, 53%) . mp 49-50°C. 31 (2H, q, Jϭ7.1 Hz), 9.15-9.40 (1H, br) . IR (KBr) cm
